CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies

被引：20

作者：

To, Van ^{[1
,2
,3
]}

Evtimov, Vera J. ^{[1
]}

Jenkin, Graham ^{[1
,2
,4
]}

Pupovac, Aleta ^{[1
]}

Trounson, Alan O. ^{[1
,2
,3
]}

Boyd, Richard L. ^{[1
]}

机构：

[1] Cartherics Pty Ltd, Notting Hill, Vic, Australia

[2] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic, Australia

[3] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic, Australia

[4] Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

CAR-T cells; CTCL; dual CARs; on-target; off-tumor toxicity; tumor heterogeneity; CHIMERIC ANTIGEN RECEPTOR; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; BRENTUXIMAB VEDOTIN; B-CELL; PHYSICIANS CHOICE; CD30; EXPRESSION; PHASE-II; CHEMOKINE RECEPTORS; THERAPEUTIC INDEX;

D O I：

10.3389/fimmu.2022.968395

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in autologous transplants, CAR-T product contamination with leukemic T cells, CAR-T fratricide (when the target antigen is present on normal T cells), and tumor heterogeneity. To address these critical challenges, innovative CAR engineering by targeting multiple antigens to strike a balance between efficacy and safety of the therapy is necessary. In this review, we discuss the current obstacles to CAR-T cell therapy and highlight potential targets in treating CTCL. Looking forward, we propose strategies to develop more powerful dual CARs that are advancing towards the clinic in CTCL therapy.

引用

页数：19

共 153 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes [J].

Agarwal, Shiwani ;

Hanauer, Julia D. S. ;

Frank, Annika M. ;

Riechert, Vanessa ;

Thalheimer, Frederic B. ;

Buchholz, Christian J. .

MOLECULAR THERAPY, 2020, 28 (08) :1783-1794

[3] CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities [J].

Ahrends, Tomasz ;

Busselaar, Julia ;

Severson, Tesa M. ;

Babala, Nikolina ;

de Vries, Evert ;

Bovens, Astrid ;

Wessels, Lodewyk ;

van Leeuwen, Fred ;

Borst, Jannie .

NATURE COMMUNICATIONS, 2019, 10 (1)

[4] CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells [J].

Alcantara, Marion ;

Tesio, Melania ;

June, Carl H. ;

Houot, Roch .

LEUKEMIA, 2018, 32 (11) :2307-2315

[5] Expression of CD47 (integrin-associated protein) decreases on red-blood cells during storage [J].

Anniss, AM ;

Sparrow, RL .

TRANSFUSION AND APHERESIS SCIENCE, 2002, 27 (03) :233-238

[6] Phenotypic and functional features of human Th17 cells [J].

Annunziato, Francesco ;

Cosmi, Lorenzo ;

Santarlasci, Veronica ;

Maggi, Laura ;

Liotta, Francesco ;

Mazzinghi, Benedetta ;

Parente, Eliana ;

Fili, Lucia ;

Ferri, Simona ;

Frosali, Francesca ;

Giudici, Francesco ;

Romagnani, Paola ;

Parronchi, Paola ;

Tonelli, Francesco ;

Maggi, Enrico ;

Romagnani, Sergio .

JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (08) :1849-1861

[7]

Balkhi MY, 2020, N BASICS CHIMERIC AN, Vp, P13, DOI [10.1016/B978-0-12-819573-4.00002-8, DOI 10.1016/B978-0-12-819573-4.00002-8]

[8]

Balkhi MY., 2020, BASICS CHIMERIC ANTI, Vp, P1, DOI [10.1016/B978-0-12-819573-4.00001-6, DOI 10.1016/B978-0-12-819573-4.00001-6]

[9] Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells [J].

Barrett, David M. ;

Zhao, Yangbing ;

Liu, Xiaojun ;

Jiang, Shuguang ;

Carpenito, Carmine ;

Kalos, Michael ;

Carroll, Richard G. ;

June, Carl H. ;

Grupp, Stephan A. .

HUMAN GENE THERAPY, 2011, 22 (12) :1575-1586

[10] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

← 1 2 3 4 5 6 7 8 9 10 →